ArticleCellular oncology (Dordrecht, Netherlands)2026
Cis-3-hexen-1-ol suppresses bladder cancer progression by inducing mitophagy via the PCK2/AMPK/mTOR signaling pathway.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCis-3-hexen-1-ol is a naturally occurring green leaf volatile widely distributed in aromatic and medicinal plants. However, its antitumor activity and underlying mechanisms in bladder cancer (BLCA) remain largely unexplored.
methodsThe antitumor effects of cis-3-hexen-1-ol were evaluated using human BLCA cell lines and mouse xenograft and metastasis models. Cell proliferation, migration, invasion, mitochondrial function, and mitophagy were assessed using CCK-8, EdU incorporation, transwell assays, mitochondrial membrane potential and ROS assays, transmission electron microscopy, and immunofluorescence. Transcriptomic profiling, molecular docking, co-immunoprecipitation, immunoblotting, and in vitro kinase assays were performed to elucidate the underlying molecular mechanisms.
resultsCis-3-hexen-1-ol significantly inhibited BLCA cell proliferation, migration, and invasion in vitro and suppressed tumor growth and lung metastasis in vivo without overt toxicity. Treatment induced mitochondrial dysfunction and robust mitophagy, as evidenced by mitochondrial fragmentation, loss of membrane potential, increased mitochondrial ROS, and enhanced recruitment of autophagy markers. Mechanistically, cis-3-hexen-1-ol activated mitophagy through the PCK2/AMPK/mTOR signaling axis. Genetic silencing of PCK2 or pharmacological inhibition of autophagic flux using 3-methyladenine markedly attenuated the antitumor and pro-mitophagic effects. Notably, biochemical analyses demonstrated that PCK2 undergoes autophosphorylation and directly phosphorylates AMPK in vitro, supporting a kinase-dependent regulatory mechanism.
conclusionsThese findings identify cis-3-hexen-1-ol as a novel mitophagy-inducing phytochemical that suppresses BLCA progression via activation of the PCK2/AMPK/mTOR pathway, highlighting its potential as a natural-product lead for targeted bladder cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.